TrialThe oncologist2018

Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma.

Ashley Ghiaseddin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.